Cosmo Pharmaceuticals N.V. (0RGI.L)
CHF 59.0
(-1.5%)
CHF 59.0
(-1.5%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 14.19 Million EUR | 23.48% |
| 2022 | 11.49 Million EUR | -12.36% |
| 2021 | 13.11 Million EUR | 129.88% |
| 2020 | 5.7 Million EUR | -7.1% |
| 2019 | 6.14 Million EUR | 56.03% |
| 2018 | 3.93 Million EUR | 21.47% |
| 2017 | 3.24 Million EUR | 40.67% |
| 2016 | 2.3 Million EUR | 2.54% |
| 2015 | 2.24 Million EUR | -32.44% |
| 2014 | 3.32 Million EUR | 16.33% |
| 2013 | 2.85 Million EUR | 30.43% |
| 2012 | 2.19 Million EUR | 19.26% |
| 2011 | 1.83 Million EUR | 41.49% |
| 2010 | 1.29 Million EUR | -14.26% |
| 2009 | 1.51 Million EUR | 0.53% |
| 2008 | 1.5 Million EUR | -2.71% |
| 2007 | 1.54 Million EUR | 60.35% |
| 2006 | 966 Thousand EUR | -26.03% |
| 2005 | 1.3 Million EUR | 27.91% |
| 2004 | 1.02 Million EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 13.9 Million EUR | -2.08% |
| 2024 Q2 | 13.9 Million EUR | 0.0% |
| 2023 Q4 | 14.19 Million EUR | 0.0% |
| 2023 Q1 | 13.45 Million EUR | 16.99% |
| 2023 Q2 | 13.45 Million EUR | 0.0% |
| 2023 FY | 14.19 Million EUR | 23.48% |
| 2023 Q3 | 14.19 Million EUR | 5.55% |
| 2022 FY | 11.49 Million EUR | -12.36% |
| 2022 Q4 | 11.49 Million EUR | 0.0% |
| 2022 Q2 | 15 Million EUR | 0.0% |
| 2022 Q1 | 15 Million EUR | 14.35% |
| 2022 Q3 | 11.49 Million EUR | -23.36% |
| 2021 Q2 | 9.92 Million EUR | 0.0% |
| 2021 FY | 13.11 Million EUR | 129.88% |
| 2021 Q3 | 13.11 Million EUR | 32.18% |
| 2021 Q1 | 9.92 Million EUR | 73.91% |
| 2021 Q4 | 13.11 Million EUR | 0.0% |
| 2020 Q4 | 5.7 Million EUR | 0.0% |
| 2020 Q2 | 6.77 Million EUR | 0.0% |
| 2020 FY | 5.7 Million EUR | -7.1% |
| 2020 Q1 | 6.77 Million EUR | 10.27% |
| 2020 Q3 | 5.7 Million EUR | -15.75% |
| 2019 Q3 | 6.14 Million EUR | -11.79% |
| 2019 Q1 | 6.96 Million EUR | 76.89% |
| 2019 Q2 | 6.96 Million EUR | 0.0% |
| 2019 FY | 6.14 Million EUR | 56.03% |
| 2019 Q4 | 6.14 Million EUR | 0.0% |
| 2018 Q1 | 3.94 Million EUR | 21.78% |
| 2018 FY | 3.93 Million EUR | 21.47% |
| 2018 Q4 | 3.93 Million EUR | 0.0% |
| 2018 Q3 | 3.93 Million EUR | -0.25% |
| 2018 Q2 | 3.94 Million EUR | 0.0% |
| 2017 Q4 | 3.24 Million EUR | 0.0% |
| 2017 FY | 3.24 Million EUR | 40.67% |
| 2017 Q1 | 2.97 Million EUR | 28.91% |
| 2017 Q2 | 2.97 Million EUR | 0.0% |
| 2017 Q3 | 3.24 Million EUR | 9.12% |
| 2016 Q2 | 2.99 Million EUR | 0.0% |
| 2016 FY | 2.3 Million EUR | 2.54% |
| 2016 Q1 | 2.99 Million EUR | 33.29% |
| 2016 Q3 | 2.3 Million EUR | -23.07% |
| 2016 Q4 | 2.3 Million EUR | 0.0% |
| 2015 Q4 | 2.24 Million EUR | 0.0% |
| 2015 Q3 | 2.24 Million EUR | -36.09% |
| 2015 FY | 2.24 Million EUR | -32.44% |
| 2015 Q2 | 3.51 Million EUR | 0.0% |
| 2015 Q1 | 3.51 Million EUR | 5.71% |
| 2014 Q4 | 3.32 Million EUR | 0.0% |
| 2014 Q2 | 4.54 Million EUR | 0.0% |
| 2014 Q1 | 4.54 Million EUR | 59.11% |
| 2014 FY | 3.32 Million EUR | 16.33% |
| 2014 Q3 | 3.32 Million EUR | -26.89% |
| 2013 Q1 | 3.37 Million EUR | 53.97% |
| 2013 FY | 2.85 Million EUR | 30.43% |
| 2013 Q4 | 2.85 Million EUR | 0.0% |
| 2013 Q3 | 2.85 Million EUR | -15.29% |
| 2013 Q2 | 3.37 Million EUR | 0.0% |
| 2012 Q4 | 2.19 Million EUR | 0.0% |
| 2012 FY | 2.19 Million EUR | 19.26% |
| 2012 Q2 | 2.78 Million EUR | 0.0% |
| 2012 Q3 | 2.19 Million EUR | -21.15% |
| 2011 Q2 | 2.24 Million EUR | 0.0% |
| 2011 Q4 | 1.83 Million EUR | 0.0% |
| 2011 FY | 1.83 Million EUR | 41.49% |
| 2010 Q2 | 2.25 Million EUR | 0.0% |
| 2010 Q4 | 1.29 Million EUR | 0.0% |
| 2010 FY | 1.29 Million EUR | -14.26% |
| 2009 Q4 | 1.51 Million EUR | 0.0% |
| 2009 FY | 1.51 Million EUR | 0.53% |
| 2008 FY | 1.5 Million EUR | -2.71% |
| 2007 FY | 1.54 Million EUR | 60.35% |
| 2006 FY | 966 Thousand EUR | -26.03% |
| 2005 FY | 1.3 Million EUR | 27.91% |
| 2004 FY | 1.02 Million EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Relief Therapeutics Holding AG | 557 Thousand CHF | -2449.013% |
| Tecan Group AG | 254.36 Million CHF | 94.418% |
| Santhera Pharmaceuticals Holding AG | 1.81 Million CHF | -683.987% |
| Basilea Pharmaceutica AG | 26.41 Million CHF | 46.24% |
| Bachem Holding AG | 340.98 Million CHF | 95.836% |
| Siegfried Holding AG | 431.93 Million CHF | 96.713% |
| Molecular Partners AG | - CHF | -Infinity% |